HMG-CoA reductase inhibitors and the risk of fractures.
暂无分享,去创建一个
H Jick | R. Schlienger | H. Jick | C. Meier | M. Kraenzlin | M E Kraenzlin | C R Meier | R G Schlienger | B Schlegel | B. Schlegel | C. Meier | Brigitta Schlegel
[1] Y. Chung,et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. , 2000, The Journal of clinical endocrinology and metabolism.
[2] P. Delmas,et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.
[3] C. Cooper,et al. Incidence of clinically diagnosed vertebral fractures: A population‐based study in rochester, minnesota, 1985‐1989 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] S. Harris,et al. Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.
[6] W. Shen,et al. Lipid clearing agents in steroid-induced osteoporosis. , 1995, Journal of the Formosan Medical Association = Taiwan yi zhi.
[7] H. Jick. A database worth saving , 1997, The Lancet.
[8] C. Furberg,et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.
[9] H. Kemper,et al. The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women , 1999, Osteoporosis International.
[10] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[11] T. Walley,et al. The UK General Practice Research Database , 1997, The Lancet.
[12] Jiang He,et al. Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials , 2000 .
[13] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[14] G. Balian,et al. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. , 1997, Clinical orthopaedics and related research.
[15] Susan S. Jick,et al. Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom , 1992 .
[16] S. Gutthann,et al. Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.
[17] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[18] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[19] H Jick,et al. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.